 |
|
Obesity predisposition traced to the brain's reward system
July 30, 2008The tendency toward obesity is directly related to the brain system that is involved in food reward and addictive behaviors, according to a new study. Researchers at Tufts University School of Medicine (TUSM) and colleagues have demonstrated a link between a predisposition to obesity and defective dopamine signaling in the mesolimbic system in rats. Their report appears in the August 2008 issue of The FASEB Journal.
The mesolimbic system is a system of neurons in the brain that secretes dopamine, a neurotransmitter or chemical messenger, which mediates emotion and pleasure. The release of the neurotransmitter dopamine in the mesolimbic system is traditionally associated with euphoria and considered to be the major neurochemical signature of drug addiction.
"Baseline dopamine levels were 50 percent lower and stimulated dopamine release was significantly attenuated in the brain reward systems of obesity-prone rats, compared with obesity-resistant rats. Defects in brain dopamine synthesis and release were evident in rats immediately after birth," said Emmanuel Pothos, PhD, assistant professor in the department of pharmacology and experimental therapeutics at TUSM and member of the neuroscience program faculty of the Sackler School of Graduate Biomedical Sciences.
"Previous research has demonstrated that food intake leads to an increase in the release of dopamine, in the circuits that mediate the pleasurable aspects of eating," Pothos explains. "Also, chronic food deprivation resulting in decreased body weight leads to decreased dopamine levels. Therefore, increased food intake may represent a compensatory attempt to restore baseline dopamine levels."
Pothos says, "These findings have important implications in our understanding of the obesity epidemic. The notion that decreased dopamine signaling leads to increased feeding is compatible with the finding from human studies that obese individuals have reduced central dopamine receptors." He speculates that an attenuated dopamine signal may interfere with satiation, leading to overeating.
Pothos and colleagues conducted their research using obesity-prone and obesity-resistant rats. Adult obesity-prone rats consumed more food and were 20% heavier than obesity-resistant rats.
The researchers measured electrically-evoked dopamine release from nerve terminals. "We also measured regulators of dopamine synthesis and release in midbrain dopamine pathways," explains Brenda Geiger, first author and graduate student in the pharmacology and experimental therapeutics department at TUSM. "Our molecular analysis suggests that the central dopamine deficits are most likely caused by reduced expression of the genes encoding two proteins, one that is involved in dopamine synthesis, and another that is a transporter responsible for packaging dopamine into vesicles from which it is later released upon stimulation."
"Obesity has so far been approached mostly as a metabolic rather than as an addictive disorder; and obesity research has primarily focused on brain systems that regulate body weight through the maintenance of energy balance. The current study challenges this approach by focusing on brain pathways implicated in pleasure and reward. These pathways could override energy balance and induce hyperphagia and obesity by altering the reward value of food, particularly palatable high-energy food, very early in life," says Pothos, who is the study's corresponding and senior author.
According to Gerald Weissmann, MD, editor-in-chief of The FASEB Journal, "Now we know why so many people stay addicted to food: it fuels the mid-brain pleasure machinery. We eat not only for nourishment, but also for pleasure. This study provides the molecular link between eating and mental health." The FASEB Journal (http://www.fasebj.org) is published by the Federation of American Societies for Experimental Biology (FASEB).
Tufts University, Health Sciences
"Previous research has demonstrated that food intake leads to an increase in the release of dopamine, in the circuits that mediate the pleasurable aspects of eating," Pothos explains. "Also, chronic food deprivation resulting in decreased body weight leads to decreased dopamine levels. Therefore, increased food intake may represent a compensatory attempt to restore baseline dopamine levels."
Pothos says, "These findings have important implications in our understanding of the obesity epidemic. The notion that decreased dopamine signaling leads to increased feeding is compatible with the finding from human studies that obese individuals have reduced central dopamine receptors." He speculates that an attenuated dopamine signal may interfere with satiation, leading to overeating.
Pothos and colleagues conducted their research using obesity-prone and obesity-resistant rats. Adult obesity-prone rats consumed more food and were 20% heavier than obesity-resistant rats.
The researchers measured electrically-evoked dopamine release from nerve terminals. "We also measured regulators of dopamine synthesis and release in midbrain dopamine pathways," explains Brenda Geiger, first author and graduate student in the pharmacology and experimental therapeutics department at TUSM. "Our molecular analysis suggests that the central dopamine deficits are most likely caused by reduced expression of the genes encoding two proteins, one that is involved in dopamine synthesis, and another that is a transporter responsible for packaging dopamine into vesicles from which it is later released upon stimulation."
"Obesity has so far been approached mostly as a metabolic rather than as an addictive disorder; and obesity research has primarily focused on brain systems that regulate body weight through the maintenance of energy balance. The current study challenges this approach by focusing on brain pathways implicated in pleasure and reward. These pathways could override energy balance and induce hyperphagia and obesity by altering the reward value of food, particularly palatable high-energy food, very early in life," says Pothos, who is the study's corresponding and senior author.
According to Gerald Weissmann, MD, editor-in-chief of The FASEB Journal, "Now we know why so many people stay addicted to food: it fuels the mid-brain pleasure machinery. We eat not only for nourishment, but also for pleasure. This study provides the molecular link between eating and mental health." The FASEB Journal (http://www.fasebj.org) is published by the Federation of American Societies for Experimental Biology (FASEB).
Tufts University, Health Sciences
Dopamine Current Events and Dopamine News RSSSinging to females makes male birds' brains happy
The melodious singing of birds has been long appreciated by humans, and has often been thought to reflect a particularly positive emotional state of the singer.
Study reveals specific gene in adolescent men with delinquent peers
Birds of a feather flock together, according to the old adage, and adolescent males who possess a certain type of variation in a specific gene are more likely to flock to delinquent peers.
Do 'light' cigarettes deliver less nicotine to the brain than regular cigarettes?
For decades now, cigarette makers have marketed so-called light cigarettes - which contain less nicotine than regular smokes - with the implication that they are less harmful to smokers' health. A new UCLA study shows, however, that they deliver nearly as much nicotine to the brain.
UNC study: Parenting can override effect of genes in how babies respond to stress
Everyone gets stressed, even babies. Now, it appears how infants respond to stress is linked to if they have a particular form of a certain gene, according to a new study from the University of North Carolina at Chapel Hill.
Early parenting plays key role in infants' physiological response to stress
In infancy, genes are the key influence on a child's ability to deal with stress. But as early as 6 months of age, parenting plays an important role in changing the impact of genes that may put infants at risk for responding poorly to stress.
First generation antipsychotic drugs as effective as newer ones in some children
Nearly every child who receives an antipsychotic medicine is first prescribed one of the second-generation, or "atypical" drugs, such as olanzapine and risperidone. However, there has never been evidence that these drugs are more effective than the older, first-generation medications.
Protein found that regulates gene critical to dopamine-releasing brain cells
Researchers have identified a protein they say appears to be a primary player in maintaining normal functioning of an important class of neurons - those brain cells that produce, excrete and then reabsorb dopamine neurotransmitters.
Abuse of painkillers can predispose adolescents to lifelong addiction
No child aspires to a lifetime of addiction. But their brains might. In new research to appear online in the journal Neuropsychopharmacology this week, Rockefeller University researchers reveal that adolescent brains exposed to the painkiller Oxycontin can sustain lifelong and permanent changes in their reward system - changes that increase the drug's euphoric properties and make such adolescents more vulnerable to the drug's effects later in adulthood.
The first autism disease genes
The autistic disorder was first described, more than sixty years ago, by Dr. Leo Kanner of the Johns Hopkins Hospital (USA), who created the new label 'early infantile autism'.
New evidence on addiction to medicines Diazepam has effect on nerve cells in the brain reward system
Addictions to medicines and drugs are thought to develop over a relatively long period of time. The process involves both structural and functional changes in brain nerve cells that are still poorly understood.
More Dopamine Current Events and Dopamine News Articles
 | Dopamine Research Advances |
 | Dumb Bells & Dopamine: A Parkinson's Success Story by Arthur, W. Curren This book is about living with Parkinson's, an incurable, debilitating disease caused by the loss of dopamine-producing cells in the brain of the afflicted person. Levodopa is the only drug that replaces some of the dopamine and exercise is the only activity that induces the brain to produce dopamine. The author uses a rigorous exercise program to reduce the dosage of levodopa and extend the... |
 | Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance, Volume 172 (Progress in Brain Research) This book provides a unique and timely multidisciplinary synthesis of our current knowledge of the anatomy, pharmacology, physiology and behavioral data of the serotonin (5-HT)-dopamine (DA) interactions. Central serotonergic and dopaminergic systems play a critical role in the regulation of normal and abnormal behaviors. Moreover, recent evidence suggests that the dysfunction of the DA and 5-HT... |
 | Dopamine, Volume 21 (Handbook of Chemical Neuroanatomy) Dopamine is a major neurotransmitter of the brain involved in the control of movement, emotion, and cognition; disturbance in dopamine function is associated with disorders like Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. This volume of the Handbook of Chemical Neuroanatomy provides a series of in depth critical reviews of our present understanding of the most... |
 | Dopamine and Glutamate in Psychiatric Disorders An illuminating summary of our current understanding of the interactive role of dopamine and glutamate in psychiatric diseases and the therapeutic strategies and possibilities for future treatment. Among the new ideas presented are hypotheses on the role of dopamine and glutamate in aggression, the glutamate system in anxiety disorders, glutamate and neurodegeneration, and on the origin and... |
 | Dopamine Transporters: Chemistry, Biology, and Pharmacology (Wiley Series in Drug Discovery and Development) Understanding the dopamine transporter can lead to new therapies for neurological disorders This book consolidates current information on the dopamine transporter (DAT) in relationto medicinal chemistry and synthesis, biology and pathology, and pharmacology. Because of DAT's role in diseases such as Parkinson's, schizophrenia, attention deficit hyperactivity disorder (ADHD), Tourette... |
 | The Dopamine Receptors (The Receptors) (The Receptors) Expert neuroscientists and pharmacologists comprehensively survey the most significant currently active areas of dopamine receptor research. Their authoritative, comprehensive chapters review all the areas of highest current interest, ranging from the molecular structure of dopamine receptors to their functions in the brain and pituitary. Their powerful critical synthesis opens the door to a... |
 | Dopamine in the Pathophysiology and Treatment of Schizophrenia: New Findings Covering the latest advances in the field, Dopamine in the Treatment of Schizophrenia, Second Edition provides a detailed explanation of the etiology and clinical presentation of the disease, especially as related to the dopamine system. Written by an international team of experts, the text identifies genetic polymorphisms that affect dopaminergic neurotransmission and their possible impact on... |
| Distribution of the 3' VNTR Polymorphism in the Human Dopamine Transporter Gene in World Populations.: An article from: Human Biology by R.j. Mitchell, S. Howlett, L. Earl, N.g. White, J. Mccomb, M.s. Schanfield, I. Briceno, S.s. Papiha, L. Osipova, G. Livshits, W.r. Leonard, M.h. Crawford This digital document is an article from Human Biology, published by Wayne State University Press on April 1, 2000. The length of the article is 4403 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Monkeys in the Middle: How One Drug Company Kept a Parkinsons Disease Breakthrough Out of Reach by Nick Nelson Some said it was a miracle drug; others called it the cure. A drug known simply as "GDNF" seemed to do the impossible by actually reversing the effects of Parkinson's disease. The miracle ended in the fall of 2004 when Amgen Inc. abruptly halted clinical trials of GDNF and denied access to the drug. In "Monkeys in the Middle", investigative reporter Nick Nelson recounts the true story of the... |
| © 2008 BrightSurf.com |